Avid Bioservices Inc (CDMO)

[biopharm]

How many patents mention targeting Phosphatidylserine and how many more are there out there? or en route? a few published online very recently ... further below on each section will include some posts, interesting Greg Lemke goes to UTSWM at that time and have there been collaborations all along ??



1) Salk Institute / Kolltan
Inventors:
Greg E. Lemke,
Lawrence C. Fritz,
Benedikt VOLLRATH,
Carla V. Rothlin

Publication date: 11 May 2017
Filing date: 20 Sep 2016
Priority date: 25 Jul 2012


2) Bayer
Inventors:
Maxine Bauzon, Terry Hermiston

filed: March 13, 2014
published online: July 4, 2017


3) Dana Farber
Inventors:
Dranoff, Glenn (Lexington, MA, US)
Jinushi, Masahisa (Tokyo, JP)

Publication Date: 08/10/2017
Filing Date: 09/26/2016


4) Institut National De La Sante Et De La Recherche Medicale (Inserm)
Inventors:
Ali Amara,
Laurent Meertens

Publication date Aug 29, 2013
Filing date Feb 20, 2013
Priority date Feb 21, 2012


****************** 1 ********************

Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine

Publication number US20170129947 A1
Publication type Application
Application number US 15/270,813

Publication date 11 May 2017
Filing date 20 Sep 2016
Priority date 25 Jul 2012

Also published as CA2879542A1, EP2877211A1, EP2877211A4, EP3184121A2, US20150164800, WO2014018535A1, Less «

Inventors:
Greg E. Lemke,
Lawrence C. Fritz,
Benedikt VOLLRATH,
Carla V. Rothlin

Original Assignee:
Salk Institute For Biological Studies,
Kolltan Pharmaceuticals, Inc.

US 20170129947 A1
Abstract
The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.

http://www.google.com.pg/patents/US20170129947?cl=en

Read the post chain, especially the one before this post AND after you read it SLOWLY, then read this specific post below SLOWLY and finally, let it all sink in that Greg Lemke is coming in house to UTSWM with Dr. Rolf Brekken as host! Something big is being set up here ...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117271035

Kolltan and PS Targeting: Part I
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117271194

Kolltan and PS Targeting: Part II
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117276385

Kolltan and PS Targeting: Part III

This is about showing some background and ties to Carla Vanina Rothlin <> Greg Lemke, because Kolltan buys out the IP patent rights of Xertrios/Greg Lemke..etc and if you have been following these posts along you should know this but just for a refresher below and if you are just joining this gets interesting because Greg Lemke is welcomed into UTSWM next month with Dr. Rolf Brekken as host.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117278813

****************** 2 ********************

Gla domains as targeting agents
US 9694048 B2

Abstract
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.


Publication number US9694048 B2
Publication type Grant
Application number US 14/773,068
PCT number PCT/US2014/026237

Publication date Jul 4, 2017
Filing date Mar 13, 2014
Priority date Mar 15, 2013

Also published as CA2905972A1, CA2905986A1, CN105008397A, CN105164152A, EP2970429A1, EP2970429A4, EP2970442A1, EP2970442A4, US20160008482, US20160106806, WO2014151535A1, WO2014151683A1, WO2014151683A8, Less «

Inventors Maxine Bauzon, Terry Hermiston

Original Assignee Bayer Healthcare, Llc

https://www.google.com/patents/US9694048

------------------------------------------------

Bayer : Patent Issued for Gla Domains as Targeting Agents (USPTO 9694048)
http://www.4-traders.com/BAYER-436063/news/Bayer-Patent-Issued-for-Gla-Domains-as-Targeting-Agents-USPTO-9694048-24749589/


****************** 3 ********************

Title:
TUMOR IMMUNITY
Document Type and Number:
United States Patent Application 20170224793
Kind Code:
A1

Abstract:
Disclosed herein are materials and methods for treating cancer. In particular, compositions for stimulating tumor immunity through modulation of MFG-E8 are provided.

Inventors:
Dranoff, Glenn (Lexington, MA, US)
Jinushi, Masahisa (Tokyo, JP)
Application Number:
15/275771

Publication Date: 08/10/2017
Filing Date: 09/26/2016

View Patent Images:
Download PDF 20170224793 PDF help
Export Citation:
Click for automatic bibliography generation

Assignee:
Dana-Farber Cancer Institute, Inc. (Boston, MA, US)

http://www.freepatentsonline.com/y2017/0224793.html

CJ: points out Dana Farber patent was a continuation...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133728587

-----------------------------------------



****************** 4 ********************

Tam receptors as virus entry cofactors
WO 2013124324 A1
Abstract
The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TAM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as flavivirus infection.

https://www.google.com/patents/WO2013124324A1?cl=en

The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry

Laurent Meertens ·
Xavier Carnec ·
Manuel Perera Lecoin ·
Rasika Ramdasi ·
Ali Amara

Abstract: Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases. However, the molecular interactions mediating DV entry are poorly understood. We determined that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors. Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors. Conversely, DV infection of susceptible...
https://www.researchgate.net/scientific-contributions/2001916760_Laurent_Meertens